相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations
Aditya Bardia et al.
ONCOLOGIST (2020)
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
Rebecca C. Arend et al.
GYNECOLOGIC ONCOLOGY (2020)
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2020)
Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Dan A. Erkes et al.
CANCER DISCOVERY (2020)
A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
Eelke Gort et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Raju K. Vaddepally et al.
CANCERS (2020)
Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
Vivek Subbiah et al.
LANCET ONCOLOGY (2020)
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
Reinhard Dummer et al.
NATURE MEDICINE (2020)
Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
Simona Stivala et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines
Pietro Paolo Vitiello et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer
Jong Woo Lee et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Claudia Iavarone et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Efficacy of MEK inhibition in patients with histiocytic neoplasms
Eli L. Diamond et al.
NATURE (2019)
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
David H. Peng et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Many ways to resistance: How melanoma cells evade targeted therapies
Ines Kozar et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2019)
HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma
Fernanda Faiao-Flores et al.
CLINICAL CANCER RESEARCH (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas et al.
NATURE MEDICINE (2019)
MEK inhibitors activate Wnt signalling and induce stem cell plasticity in colorectal cancer
Tianzuo Zhan et al.
NATURE COMMUNICATIONS (2019)
447PDPhase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours
R B Corcoran et al.
ANNALS OF ONCOLOGY (2019)
LBA61A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer
D M Gershenson et al.
ANNALS OF ONCOLOGY (2019)
PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
Amanda M. Smith et al.
Oncotarget (2019)
Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells
Masanobu Tsubaki et al.
CANCERS (2019)
Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
Marta Llaurado Fernandez et al.
CANCER CELL INTERNATIONAL (2019)
Heterogeneous alteration of the ERBB3-MYC axis associated with MEK inhibitor resistance in a KRAS-mutated low-grade serous ovarian cancer patient
Ilaria Colombo et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma
Alain P. Algazi et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
Eric Van Cutsem et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
Vivek Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Otto Kauko et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Encorafenib and Binimetinib: First Global Approvals
Matt Shirley
DRUGS (2018)
SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models
Carmine Fedele et al.
CANCER DISCOVERY (2018)
Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
Mal Irvine et al.
ONCOGENESIS (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
MEK inhibitors in oncology: a patent review (2015-Present)
Debarshi Kar Mahapatra et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
Michael A. Davies et al.
LANCET ONCOLOGY (2017)
Current Development Status of MEK Inhibitors
Ying Cheng et al.
MOLECULES (2017)
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers
Chaoyang Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Hashem O. Alsaab et al.
FRONTIERS IN PHARMACOLOGY (2017)
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Edmund Poon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer
Michele Milella et al.
SCIENTIFIC REPORTS (2017)
Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents
Ciska Verbaanderd et al.
ECANCERMEDICALSCIENCE (2017)
Overcoming resistance to BRAF inhibitors
Imanol Arozarena et al.
ANNALS OF TRANSLATIONAL MEDICINE (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Sticking It to Cancer with Molecular Glue for SHP2
Hao Ran et al.
CANCER CELL (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
A combinatorial strategy for treating KRAS-mutant lung cancer
Eusebio Manchado et al.
NATURE (2016)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer
Hidenori Kitai et al.
CANCER DISCOVERY (2016)
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
G. R. Blumenschein et al.
ANNALS OF ONCOLOGY (2015)
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
Willy Hugo et al.
CELL (2015)
A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
FAK signaling in human cancer as a target for therapeutics
Brian Y. Lee et al.
PHARMACOLOGY & THERAPEUTICS (2015)
A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors
Philippe L. Bedard et al.
CLINICAL CANCER RESEARCH (2015)
MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Christopher J. Caunt et al.
NATURE REVIEWS CANCER (2015)
Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kristel Kemper et al.
CANCER RESEARCH (2014)
Resistance to RAF Inhibitors Revisited
Edward Hartsough et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations
X. Chen et al.
ONCOGENE (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle et al.
CANCER DISCOVERY (2014)
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
Chong Sun et al.
CELL REPORTS (2014)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma
Hemant K. Bid et al.
CLINICAL CANCER RESEARCH (2013)
BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Dennie T. Frederick et al.
CLINICAL CANCER RESEARCH (2013)
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Nguyen Tan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
John Farley et al.
LANCET ONCOLOGY (2013)
Vemurafenib Potently Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in BRAFV600E Melanoma Cells
Daniela Beck et al.
SCIENCE SIGNALING (2013)
Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
James S. Duncan et al.
CELL (2012)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
Osamu Takahashi et al.
CLINICAL CANCER RESEARCH (2012)
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
D. Neil Hayes et al.
CLINICAL CANCER RESEARCH (2012)
Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Junping Jing et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
James G. Greger et al.
MOLECULAR CANCER THERAPEUTICS (2012)
The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward
Mark W. Kieran et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Bingbing Dai et al.
CANCER RESEARCH (2011)
Autophagy as a target for anticancer therapy
Filip Janku et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status
Marie C. Zipser et al.
PIGMENT CELL & MELANOMA RESEARCH (2011)
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Mohammad Atefi et al.
PLOS ONE (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim
Jieru Meng et al.
PLOS ONE (2010)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERKI/2 signalling and/or strong P13K signalling in colorectal cancer cell lines
Kathryn Balmanno et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
MEK1 mutations confer resistance to MEK and B-RAF inhibition
Caroline M. Emery et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/MEK/ERK Pathway
Kwong-Kwok Wong
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway
Judith S. Sebolt-Leopold
CLINICAL CANCER RESEARCH (2008)
The mir-200 family and mir-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1
Philip A. Gregory et al.
NATURE CELL BIOLOGY (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
James A. McCubrey et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
ERK implication in cell cycle regulation
Jean-Claude Chambard et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2007)
Protein kinase C and other diacylglycerol effectors in cancer
Erin M. Griner et al.
NATURE REVIEWS CANCER (2007)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant
D Tsavachidou et al.
CANCER RESEARCH (2004)
CSF-1 regulation of the wandering macrophage: complexity in action
FJ Pixley et al.
TRENDS IN CELL BIOLOGY (2004)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
The Raf/MEK/ERK pathway:: new concepts of activation
C Peyssonnaux et al.
BIOLOGY OF THE CELL (2001)
Blocking oncogenic Ras signaling for cancer therapy
AA Adjei
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death
Z Herceg et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Mammalian MAP kinase signalling cascades
LF Chang et al.
NATURE (2001)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
分享论文
